疏调稳糖平鼾方治疗痰浊郁热型2型糖尿病合并阻塞性睡眠呼吸暂停临床研究OA
Shutiao Wentang Pinghan formula in the treatment of type 2 diabetes mellitus combined with obstructive sleep apnea patients of phlegm-heat stagnation syndrome
目的:探讨疏调稳糖平鼾方治疗痰浊郁热型 2 型糖尿病(T2DM)合并阻塞性睡眠呼吸暂停(OSA)的临床疗效.方法:选取 88 例T2DM合并 OSA患者,使用随机数字表法分组.对照组给予生活方式干预和常规降糖、降压、降脂的药物和持续气道正压通气治疗,试验组在对照组基础上合用疏调稳糖平鼾方进行干预,两组疗程均为 12周.在干预 12 周后,评估两组患者的糖化血红蛋白(HbA1c)、空腹血糖(FBG)、餐后 2 h血糖(2hPG)、呼吸暂停低通气指数(AHI)、平均血氧饱和度(MSpO2)、最低血氧饱和度(LSpO2)、氧减指数(ODI)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯葡萄糖指数(TyG)、血尿酸(UA)、全身免疫炎症指数(SII)、中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)、中性粒细胞/血小板比值(NPR)、体重指数(BMI)、腰臀比(WHR)、内脏脂肪面积(VAT)、皮下脂肪面积(SAT)、匹兹堡睡眠质量指数(PSQI)、Epworth嗜睡评分(ESS)和中医证候积分,并进行安全性评估.结果:经 12 周治疗后,试验组的 HbA1c、FBG、2hPG、AHI、ODI、TC、TG、LDL-C、TyG、PSQI、ESS 和中医证候评分低于对照组,差异均有统计学意义(P<0.05).试验组的 MSpO2 和 LSpO2 高于对照组,差异均有统计学意义(P<0.05).两组的 HDL-C、UA、BMI、WHR、VAT、SAT、SII、NLR、PLR比较,差异均无统计学意义(P>0.05).试验组总有效率高于对照组(P<0.05),两组安全性指标未见明显异常.结论:疏调稳糖平鼾方治疗痰浊郁热型 T2DM合并 OSA 患者的临床疗效及安全性良好.
Objective:To evaluate the clinical efficacy and safety of Shutiao Wentang Pinghan formula in patients with Type 2 diabetes mellitus(T2DM)and obstructive sleep apnea(OSA)of phlegm-heat stagnation syndrome.Methods:A total of 88 patients with T2DM combined with OSA were randomly divided by the random number table method.The control group was given lifestyle intervention and conventional hypoglycemic,antihypertensive,lipid-lowering drugs and continuous positive airway pressure treatment.The experimental group was treated with the addi-tion of the Shutiao Wentang Pinghan formula on the basis of the control group.The treatment course for both groups was 12 weeks.HbA1c,FBG,2hPG,AHI,MSpO2,LSpO2,ODI,TC,TG,LDL-C,HDL-C,TyG,UA,SII,NLR,PLR,NPR,BMI,WHR,VAT,SAT,PSQI,ESS and TCM syndrome scores were measured at the time of enrollment and after 12 weeks of intervention.Safety was also evaluated.Results:After 12 weeks of treatment,the levels of HbA1c,FBG,2hPG,AHI,ODI,TC,TG,LDL-C,TyG,PSQI,ESS and TCM syndrome scores in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of MSpO2 and LSpO2 in the experimental group were higher than those in the control group,with statistically significant differences(P<0.05).There were no statistically significant differences in HDL-C,UA,BMI,WHR,VAT,SAT,SII,NLR and PLR between the two groups(P>0.05).The total efficacy rate of the experimental group was higher than that of the control group(P<0.05),and no serious adverse reactions were found in both groups.Conclusion:Shutiao Wentang Pinghan formula exhibit good clinical efficacy and safety in patients with T2DM combined with OSA of the phlegm-heat stagnation type.
CHEN Jiaqi;LIN Shuzhong;CHEN Zeyao;XU Jinghan;LIU Tianjiao;WANG Li;PIAO Chunli
Department of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,ChinaDepartment of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,ChinaDepartment of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,ChinaDepartment of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,ChinaDepartment of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,ChinaDepartment of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,ChinaDepartment of Endocrinology,Shenzhen Hospital(Futian)of Guangzhou University of Chinese Medicine,Shenzhen 518000,China
医药卫生
疏调稳糖平鼾方小陷胸汤解毒通络调肝方2型糖尿病阻塞性睡眠呼吸暂停糖脂代谢痰浊郁热
Shutiao Wentang Pinghan formulaXiaoxianxiong decoctionJiedu Tongluo Tiaogan formulaType 2 diabetes mellitusObstructive sleep apneaGlycolipid metabolismPhlegm-heat stagnation
《陕西中医》 2026 (1)
40-47,8
国家自然科学基金资助项目(82374380,82405256)中国中医药科技发展中心中西医协同慢病管理研究项目(CXZH2024170)广东省基础与应用基础研究基金资助项目(2023A1515220236)广东省深圳市"医疗卫生三名工程"项目资助(SZZYSM202202010)广东省深圳市福田区卫生健康系统科研项目(FTWS2022036,FTWS060)广州中医药大学深圳医院(福田)科研专项(GZYSY2024009)
评论